NARCOMS Registry: A Multiple Sclerosis Registry
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- University of Texas Southwestern Medical Center
- Study ID
- NCT01018537
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This project is based on the idea that we can learn about the complexities of MS by following disease and treatment patterns in a large group of people over several years. The information gathered is used for research only. Results are presented in summary form only. All details submitted by registry participants is strictly confidential. To participate in NARCOMS complete the baseline enrollment survey online through www.narcoms.org (or directly using the following link: https://redcap.link/py2rnyyn) or you can request a mail-in survey be sent to you by emailing [email protected]. You will be asked to update your information, online or by mail, twice a year. Each update survey typically takes less than 20 minutes to complete. There is no cost to participate. For your participation you are offered a free subscription to the NARCOMS quarterly magazine, NARCOMS Now. NARCOMS Now provides a reliable source of information about the latest in MS research and disease management. You can stop participating in the registry at any time. You may also receive additional surveys or information on clinical trials. You are not obligated to participate and these additional studies will always come directly from NARCOMS. Your contact information will not be shared or sold to other parties.
Key Dates
- Start date
- Jan 31, 1996
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2050
- Completion
- Dec 31, 2050
Study Design
- Enrollment
- 50,000 participants (estimated)
Primary Outcome Measure
Disease progression over time of follow up [ Time Frame: up to 15 years ]
Central Contacts
- NARCOMS Team1-214-648-4583
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT Southwestern Medical Center | Dallas | Texas | 75390-8806 | Amber Salter, Ph.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Dallas, TX
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Non-invasive BCI-controlled Assistive DevicesRecruiting · University of Texas at Austin · Austin, Texas
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MSRecruiting · The Methodist Hospital Research Institute · Houston, Texas